First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

BACKGROUND: The phase 3 KEYNOTE-590 (NCT03189719) study showed first-line pembrolizumab plus chemotherapy significantly prolonged overall survival and progression-free survival versus placebo plus chemotherapy in patients with advanced unresectable or metastatic adenocarcinoma or squamous cell carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Takashi, Hara, Hiroki, Tsuji, Akihito, Yasui, Hisateru, Muro, Kei, Satoh, Taroh, Ogata, Takashi, Ishihara, Ryu, Goto, Masahiro, Baba, Hideo, Nishina, Tomohiro, Han, Shirong, Sakata, Tomoko, Yatsuzuka, Naoyoshi, Doi, Toshihiko, Kato, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436840/
https://www.ncbi.nlm.nih.gov/pubmed/35668304
http://dx.doi.org/10.1007/s10388-022-00920-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436840/
https://www.ncbi.nlm.nih.gov/pubmed/35668304
http://dx.doi.org/10.1007/s10388-022-00920-x

Ejemplares similares